1185878-99-2
1185878-99-2
Chemical Structure
7-Methylxanthine-d33
- CAS No.: 1185878-99-2
- Formula:C6H3D3N4O2
- Molecular Weight:169.16
InChIKey: PFWLFWPASULGAN-FIBGUPNXSA-N
SMILES: O=C1C2=C(N=CN2C([2H])([2H])[2H])NC(N1)=O
Biological Activity: 7-Methylxanthine-d3 is deuterium labeled 7-Methylxanthine. 7-Methylxanthine, a methyl derivative of xanthine, is one of the purine components in urinary calculi[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
7-Methylxanthine-d33 | 99.31% | 7-Methylxanthine-d3 is deuterium labeled 7-Methylxanthine. 7-Methylxanthine, a methyl derivative of xanthine, is one of the purine components in urinary calculi. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7-Methylxanthine (Standard) | ≥98% | 7-Methylxanthine (Standard) is the analytical standard of 7-Methylxanthine. This product is intended for research and analytical applications. 7-Methylxanthine is an orally active methyl derivative of xanthine and a non-selective adenosine receptor antagonist. 7-Methylxanthine is also one of the purine components of human urinary calculi. 7-Methylxanthine has anti-myopia activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7-Methylxanthine | 99.94% | 7-Methylxanthine is an orally active methyl derivative of xanthine and a non-selective adenosine receptor antagonist. 7-Methylxanthine is also one of the purine components of human urinary calculi. 7-Methylxanthine has anti-myopia activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Caubet MS, et al. Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J Pharm Biomed Anal. 2004 Feb 4;34(2):379-89. [Content Brief]
